8 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 35418303 | Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells. | 2022 Apr 13 | 1 |
2 | 35430566 | SLFN12 Over-expression Sensitizes Triple Negative Breast Cancer Cells to Chemotherapy Drugs and Radiotherapy. | 2022 May-Jun | 1 |
3 | 34081985 | Checkpoint kinases are required for oocyte meiotic progression by the maintenance of normal spindle structure and chromosome condensation. | 2021 Aug 15 | 1 |
4 | 32857208 | Radiosensitization of NSCLC cells to X-rays and carbon ions by the CHK1/CHK2 inhibitor AZD7762, Honokiol and Tunicamycin. | 2020 Nov | 2 |
5 | 30633885 | Acetyl-macrocalin B suppresses tumor growth in esophageal squamous cell carcinoma and exhibits synergistic anti-cancer effects with the Chk1/2 inhibitor AZD7762. | 2019 Feb 15 | 1 |
6 | 24362713 | Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary. | 2014 Jan | 1 |
7 | 23892959 | Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours. | 2013 Sep | 1 |
8 | 22189968 | Potentiation of the novel topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell checkpoint and Chk1-Chk2 inhibitor AZD7762. | 2012 Feb 15 | 3 |